Primary sclerosing cholangitis hospitalizations in the United States: characteristics and predictors of clinical outcomes.
ERCP
liver transplantation
primary sclerosing cholangitis
Journal
Proceedings (Baylor University. Medical Center)
ISSN: 0899-8280
Titre abrégé: Proc (Bayl Univ Med Cent)
Pays: United States
ID NLM: 9302033
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
Primary sclerosing cholangitis (PSC) is a chronic progressive disease that primarily affects the medium and large biliary ducts. This study investigated the baseline characteristics and predictors of clinical outcomes among hospitalized patients with PSC in the US. Using the National Inpatient Sample database from 2018 to 2020, we included adults with a principal diagnosis of PSC. Our study included 2585 adult hospitalizations. The prevalence of cirrhosis, ulcerative colitis (UC), Crohn's disease (CD), and cholangiocarcinoma among hospitalized PSC patients was 44.5%, 32.3%, 13.15%, and 5.2%, respectively. Over a third of patients (38.1%) underwent endoscopic retrograde cholangiopancreatography (ERCP). UC, CD, cholangiocarcinoma, and autoimmune hepatitis had no impact on mortality, length of stay, or ERCP utilization. Interestingly, individuals of Asian/Pacific Islander ethnicity had higher odds of undergoing ERCP compared to White ethnicity (odds ratio 4.67, 95% confidence interval 1.25-17.4). Conversely, patients with cirrhosis and liver transplant recipients were less likely to undergo ERCP. This is the first nationwide study to assess the clinical characteristics and outcomes of hospitalized patients with PSC. It highlights various factors associated with increased utilization of ERCP, longer length of stay, and increased inpatient mortality. Further research is warranted to explore these associations.
Sections du résumé
Background
UNASSIGNED
Primary sclerosing cholangitis (PSC) is a chronic progressive disease that primarily affects the medium and large biliary ducts.
Methods
UNASSIGNED
This study investigated the baseline characteristics and predictors of clinical outcomes among hospitalized patients with PSC in the US. Using the National Inpatient Sample database from 2018 to 2020, we included adults with a principal diagnosis of PSC.
Results
UNASSIGNED
Our study included 2585 adult hospitalizations. The prevalence of cirrhosis, ulcerative colitis (UC), Crohn's disease (CD), and cholangiocarcinoma among hospitalized PSC patients was 44.5%, 32.3%, 13.15%, and 5.2%, respectively. Over a third of patients (38.1%) underwent endoscopic retrograde cholangiopancreatography (ERCP). UC, CD, cholangiocarcinoma, and autoimmune hepatitis had no impact on mortality, length of stay, or ERCP utilization. Interestingly, individuals of Asian/Pacific Islander ethnicity had higher odds of undergoing ERCP compared to White ethnicity (odds ratio 4.67, 95% confidence interval 1.25-17.4). Conversely, patients with cirrhosis and liver transplant recipients were less likely to undergo ERCP.
Conclusion
UNASSIGNED
This is the first nationwide study to assess the clinical characteristics and outcomes of hospitalized patients with PSC. It highlights various factors associated with increased utilization of ERCP, longer length of stay, and increased inpatient mortality. Further research is warranted to explore these associations.
Identifiants
pubmed: 37829220
doi: 10.1080/08998280.2023.2254196
pii: 2254196
pmc: PMC10566382
doi:
Types de publication
Journal Article
Langues
eng
Pagination
700-704Informations de copyright
Copyright © 2023 Baylor University Medical Center.
Déclaration de conflit d'intérêts
A poster based on this project was presented at the Digestive Disease Week 2023 in Chicago, IL, USA. The authors report no funding or conflicts of interest.
Références
J Hepatol. 2017 Dec;67(6):1298-1323
pubmed: 28802875
Gastroenterology. 2013 Sep;145(3):521-36
pubmed: 23827861
Hepatology. 2023 Feb 1;77(2):659-702
pubmed: 36083140
Am J Gastroenterol. 2000 Sep;95(9):2333-7
pubmed: 11007238
Am J Surg. 1966 Jan;111(1):23-38
pubmed: 5901372
Hepatol Int. 2021 Feb;15(1):6-20
pubmed: 33377990
Gastroenterology. 2017 Jun;152(8):1975-1984.e8
pubmed: 28274849
BMC Gastroenterol. 2011 Jul 18;11:83
pubmed: 21767410
J Clin Gastroenterol. 2014 Feb;48(2):e19-21
pubmed: 24402121
Hawaii J Health Soc Welf. 2021 Feb 1;80(4):80-87
pubmed: 33889846
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003626
pubmed: 21249655
PLoS One. 2015 Apr 02;10(3):e0120574
pubmed: 25837669
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
Gastroenterology. 2003 Nov;125(5):1364-9
pubmed: 14598252
Clin Gastroenterol Hepatol. 2018 Apr;16(4):591-593
pubmed: 29102704
Hepatology. 2013 Dec;58(6):2045-55
pubmed: 23775876
Gastroenterology. 1994 Feb;106(2):494-9
pubmed: 8299916